NGEN
NervGen Pharma Corp.
NASDAQ: NGEN · HEALTHCARE · BIOTECHNOLOGY
$3.63
-3.20% today
Updated 2026-04-30
Market cap
$311.58M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.45
Dividend yield
—
52W range
$2 – $6
Volume
0.2M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$10.16
+179.89%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-10.13M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-15.29M | $-16.89M | $-16.68M | $-44.12M | $-31.70M |
| EPS | — | — | — | — | $-0.45 |
| Free cash flow | $-13.13M | $-8.53M | $-11.70M | $-19.50M | $-10.13M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
NervGen Pharma Corp. trades at $3.63. Our Smart Value Score of 17/100 indicates the stock is weak.
Frequently asked questions
What is NervGen Pharma Corp.'s stock price?
NervGen Pharma Corp. (NGEN) trades at $3.63.
Is NervGen Pharma Corp. overvalued?
Smart Value Score 17/100 (Grade F, Strong Sell).
What is the price target of NervGen Pharma Corp. (NGEN)?
The analyst target price is $10.16, representing +179.9% upside from the current price of $3.63.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-1,458.00%
Beta0.99
50D MA$4.04
200D MA$3.54
Shares out0.08B
Float0.07B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—